FINAL DIAGNOSIS: ORGANOPHOSPHATE INSECTICIDE POISONING
Case Discussion - Insecticide Poisoning:
Pet AgreeTM is a flea dip which contains chlorpyrifos at a 3.84% concentration mixed with an inert vehicle. The ingestion of this organophosphate insecticide produced symptoms related to impaired degradation of acetylcholine, including pinpoint pupils, sweating, drooling, and, most dramatically, paralysis. Confirmation of the clinically suspected exposure was obtained through the identification of the active ingredient, in a urine sample from the patient, by gas chromatography-mass spectroscopy.
The neuro-physiological deficits observed in patients with organophosphate insecticide poisoning is related to irreversible binding of the organophophate to the enzyme that degrades acetylcholine at nerve endings. In this patient, the earliest measurement of total serum cholinesterase showed activity that was only 0.5% of the lower range of normal activity. The dibucaine number, which is not usually interpreted in cases like this (see the section on cholinesterase, acetylcholinesterase, and dibucaine index), showed much less inhibition than normal, possibly because all of the enzyme that would normally be inhibited had already been irreversibly inhibited by the organophophate insecticide, and because the available activity of the enzyme was already low. By the second day of hospitalization, the cholinesterase activity had begun to increase.
This patient was treated with atropine and pralidoxime. The atropine acted to block the muscarinic effects of increased acetylcholine on the respiratory, gastrointestinal, and cardiovascular systems. The pralidoxime acted to 'regenerate" the damaged acetylcholinesterase. A measure of the success of the pralidoxime is that the red cell acetylcholinesterase activity had returned to normal levels by about 3 1/2 days after the poisoning.
The patient recovered without apparent permanent sequelae. The mild anemia noted is unrelated to the organophosphate; the borderline hyponatremia was probably related to intravenous therapy.
SELECTED READINGS: